Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | USP2 | O75604 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.65 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | APAF1 | O14727 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9359369 | 0.92 | HTT (0.61) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8757800 | 0.92 | HTT (0.61) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4019008 | 0.90 | HTT (0.62) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8027851 | 0.87 | MEN1 (0.54) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10899000 | 0.86 | HTT (0.57) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11522071 | 0.86 | HTT (0.69) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11262533 | 0.86 | HTT (0.67) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8024275 | 0.84 | CYP3A4 (0.65) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13384532 | 0.84 | HTT (0.51) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12362591 | 0.84 | HTT (0.51) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132298-A1 | A METHOD FOR PRODUCING INTERFERENCE ELEMENTS | BASF SE (DE) | 2026-05-14 | — | — | US | disclosed |
| US-12515253-B2 | Compositions, comprising silver nanoplatelets | BASF SE (DE) | 2026-01-06 | — | — | US | disclosed |
| US-20250268293-A1 | PROTEIN SWEETENERS | AMAI PROTEINS LTD. (IL) | 2025-08-28 | — | — | US | disclosed |
| EP-4547694-A1 | PROTEIN SWEETENERS | Amai Proteins Ltd. (IL) | 2025-05-07 | — | — | EP | disclosed |
| US-12208447-B2 | Compositions, comprising silver nanoplatelets | BASF SE (DE) | 2025-01-28 | — | — | US | disclosed |
| US-20240309174-A1 | COMPOSITIONS, COMPRISING SILVER NANOPLATELETS | BASF SE (DE) | 2024-09-19 | — | — | US | disclosed |
| EP-4423176-A1 | A METHOD FOR PRODUCING INTERFERENCE ELEMENTS | BASF SE (DE) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024003917-A1 | PROTEIN SWEETENERS | AMAI PROTEINS LTD. (IL) | 2024-01-04 | — | — | WO | disclosed |
| CN-117203007-A | Composition comprising silver nanoplates | 巴斯夫欧洲公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-112912191-B | Composition comprising silver nanoplatelets | 巴斯夫欧洲公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116547090-A | Composition comprising silver nanoplates | 巴斯夫欧洲公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230241675-A1 | COMPOSITIONS, COMPRISING PLATELET-SHAPED TRANSITION METAL PARTICLES | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023072740-A1 | A METHOD FOR PRODUCING INTERFERENCE ELEMENTS | BASF SE (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4139070-A1 | COMPOSITIONS, COMPRISING PLATELET-SHAPED TRANSITION METAL PARTICLES | BASF SE (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115279518-A | Composition comprising flaky transition metal particles | 巴斯夫欧洲公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022167377-A1 | COMPOSITIONS, COMPRISING SILVER NANOPLATELETS | BASF SE (DE) | 2022-08-11 | — | — | WO | disclosed |
| US-20220220284-A1 | COMPOSITIONS, COMPRISING SILVER NANOPLATELETS | BASF SE (DE) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132298-A1 | A METHOD FOR PRODUCING INTERFERENCE ELEMENTS | COPE, COPB2, C9 | MEN1 1496/4885KMT2A 1765/4885MAPK1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.